Saturday, August 29, 2015

FDA, drugmakers say they've solved two drug shortages

The FDA and several drug companies said Tuesday they have reached agreements to alleviate shortages for the drugs methotrexate and Doxil.

FDA, drugmakers say they've solved two drug shortages

0 comments

The U.S. Food and Drug Administration and several pharmaceutical companies said Tuesday they have reached agreements to alleviate shortages for the drugs methotrexate and Doxil.

Methotrexate is used to treat children with a form of leukemia and others with tumors of the breast and lungs. Doxil is used to treat ovarian cancer and multiple myeloma.

“A drug shortage can be a frightening prospect for patients and President Obama made it clear that preventing these shortages from happening is a top priority of his administration,” FDA Commissioner Margaret A. Hamburg, M.D., said in a statement. “Through the collaborative work of FDA, industry, and other stakeholders, patients and families waiting for these products or anxious about their availability should now be able to get the medication they need.”

Hamburg appeared at a midday news conference at FDA headquarters in suburban Washington, D.C., with prominent cancer doctors and top executives from Hospira and APP Pharmaceuticals, two of the generic manufacturers involved.

The FDA delivered on Friday an expedited approval of APP's drug application for methotrexate.

Meanwhile, Hospira, which was already producing the drug, got rushed approval to bring ingredients from its overseas factories and suppliers.

"I’m thrilled to relay that, 24 hours ago, we began directly shipping 31,000 vials of new product — enough to address more than a month’s worth of demand — and it is being received in hundreds of our nation’s hospitals and treatment centers today," Hospira chief executive officer Michael Ball said at the news conference.

As for Doxil (doxorubicin hydrochloride liposome injection), the FDA said it temporarily relaxed rules and is allowing the importation of a replacement drug, Lipodox, which is expected to end the shortage and fully meet patient needs in the coming weeks. Lipodox is made by the Indian company Sun Pharma Global.

The shortages of both drugs were related to the shutdown because of manufacturing problems at the plant run by Ben Venue Laboratories, Inc., in Ohio. Ben Venue is a subsidiary of Boehringer Ingelheim GmbH. Doxil is a product of the Johnson & Johnson subsidiary Janssen Research & Development LLC., which in turn contracted with Ben Venue Laboratories to make Doxil.

It was unclear what costs would be incurred by APP or Hospira for the newly-announced production or what prices they will charge for the drug.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell
Also on Philly.com:
letter icon Newsletter